A pioneering technology to treat sepsis

Sepsis affects over 26 million people worldwide each year – more than 5 million people die each year because of sepsis. The major treatment of sepsis today is antibiotic treatment. The disease is becoming increasingly difficult to cure due to antibiotic resistant bacteria.

Sangair has developed a groundbreaking system to treat Sepsis. The system allows for a mild treatment of the patient’s blood using active oxygen. The treatment is estimated to take one hour for an adult.

Sangair – a groundbreaking system

The Sangair system will perform a mild treatment of the patient’s blood using active oxygen. The treatment is done by extracting blood from the radial artery of the patient. The blood is cooled down to 7°C through a heat exchanger, and active oxygen in the form of micro-bubbles is dispersed into the blood using a sintered gas dispenser.

The gas will travel with the blood for about 10 seconds and then be degassed by a gas and foam separator. The blood is then warmed up to 37°C and returned to the venous system of the patient.

Based on extensive experience of the use of active oxygen, Sangair’s method will most likely have a significant effect on E. coli. It also appears to have the same effect on Streptococcus. Sepsis caused by E. coli and Streptococcus represent a majority of the sepsis cases.

Technically, the Sangair device will consist of a computerized machine and a disposable set that enables user friendly and controlled treatment with active oxygen. It can be described as a combination of a dialysis machine and a heater-cooler unit from the heart-lunch machine industry.

 

About sepsis

Sepsis is a systemic infection that many times leads to complications and deathP1FP. Bacteria, primarily E. coli, Streptococcus and Staphylococcus are behind 90% of sepsis cases. Another 10% is caused by fungi and a minuscule percentage of viruses.

World-wide, 26 million people develop sepsis each year, and as many as 5 million people die from the disease. Daily 600 persons in the US die due to sepsis. Severe sepsis and septic shock patients account for up to 20% of all intensive care unit (ICU) admissions and require expensive and highly variable treatment and diagnostic procedures.

The most common treatment of sepsis is the use of antibiotics. WHO reports that antibiotic resistance is rising to dangerously high levels in all parts of the world, threatening the ability to treat, among other diseases, sepsis. It is harder, and sometimes impossible to treat these diseases as antibiotics become less effectiveP4FP.

Background

In 2015, Johan Sjöholm and Professor Lennart Ljunggren came up with the invention to treat blood of sepsis patients through a method that combines prior art with new discoveries. A patent application for the invention was submitted during the fall of 2015.

They had previously discovered that Escherichia coli (E. coli) microorganisms were killed using active oxygen with no adverse events of proteins and fats. Tests also showed that the same terminative effect as with pasteurization at 72°C was achieved when subjecting fluids containing bacteria to active oxygen.

In 2016 Sangair was founded and the first animal trial was carried out in Lund in August 2016.

In September 2016, an agreement was signed between the Lund University Innovation Centre (Luic) and the founders.

Today Sangair is conducting studies on E -coli contaminated animals. The plan is to carry out clinical studies in the next couple of years.

Contact

Sangair is located at Medicon Village in Lund and at Karolinska Science Park in Solna, Sweden.

If you need more information do not hesitate to contact us.

Sangair AB
Nanna Svartz väg 4
171 65 Solna
Henrik.rundgren@sangair.se
0733-643959